Evidence map›Paper›PMID 35798820›Full record

ArticleScientific reports2022

Performance evaluation of a non-invasive one-step multiplex RT-qPCR assay for detection of SARS-CoV-2 direct from saliva.

Harry H Jenkins, Ana A Tellechea Lopez, Francesco Saverio Tarantini, Hannah Tomlin, Danielle Scales, I-Ning Lee, Siyu Wu, Ralph Hyde, Katarzyna Lis-Slimak, Timothy Byaruhanga and 15 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 1 institution in 1 country.

Harry H JenkinsSchool of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK. harry.jenkins1@nottingham.ac.uk.
Ana A Tellechea LopezSchool of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
Francesco Saverio TarantiniSchool of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
Hannah TomlinSchool of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
Danielle ScalesSchool of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
I-Ning LeeSchool of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
Siyu WuSchool of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
Ralph HydeSchool of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
Katarzyna Lis-SlimakSchool of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
Timothy ByaruhangaSchool of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
Jamie L ThompsonSchool of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
Sara Pijuan-GalitoSchool of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
Lara DoolanSchool of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
Kazuyo KanekoSchool of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
Penny GwynneSchool of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
Caroline ReffinSchool of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
Emily ParkSchool of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
Jayasree DeySchool of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
Jack HillSchool of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
Asta Arendt-TranholmSchool of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
Amy StroudSchool of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
Moira PetrieSchool of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
Chris Denning *School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK. chris.denning@nottingham.ac.uk.
Andrew V Benest *School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK. andrew.benest@nottingham.ac.uk.
Claire Seedhouse *School of Medicine, Biodiscovery Institute, University of Nottingham Asymptomatic Testing Service (UoNATS), University of Nottingham, University Park, Nottingham, NG7 2RD, UK. claire.seedhouse@nottingham.ac.uk.
University of Nottingham · GB

Funding

British Heart Foundation PG/14/59/31000British Heart Foundation PG/18/31/33759British Heart Foundation PG/21/10545British Heart Foundation SP/15/9/31605Medical Research Council MC_PC_20027Medical Research Council MR/L012618/1
6 · The paper itself

Abstract

Polymerase chain reaction (PCR) has proven to be the gold-standard for SARS-CoV-2 detection in clinical settings. The most common approaches rely on nasopharyngeal specimens obtained from swabs, followed by RNA extraction, reverse transcription and quantitative PCR. Although swab-based PCR is sensitive, swabbing is invasive and unpleasant to administer, reducing patient compliance for regular testing and resulting in an increased risk of improper sampling. To overcome these obstacles, we developed a non-invasive one-step RT-qPCR assay performed directly on saliva specimens. The University of Nottingham Asymptomatic Testing Service protocol simplifies sample collection and bypasses the need for RNA extraction, or additives, thus helping to encourage more regular testing and reducing processing time and costs. We have evaluated the assay against the performance criteria specified by the UK regulatory bodies and attained accreditation (BS EN ISO/IEC 17,025:2017) for SARS-CoV-2 diagnostic testing by the United Kingdom Accreditation Service. We observed a sensitivity of 1 viral copy per microlitre of saliva, and demonstrated a concordance of > 99.4% between our results and those of other accredited testing facilities. We concluded that saliva is a stable medium that allows for a highly precise, repeatable, and robust testing method.

Indexed as

COVID-19SARS-CoV-2Clinical Laboratory TechniquesCOVID-19 TestingHumansNasopharynxRNA, ViralSalivaSensitivity and SpecificitySpecimen HandlingRNA, Viral

Identifiers

PMID35798820
PMCPMC9261881
OpenAlexW4284701277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.